|Day Low/High||336.00 / 351.22|
|52 Wk Low/High||17.91 / 178.50|
Also, there's reason to turn J&J's one shot jab into a two shot vaccine just like the rest.
In many respects, the Monday's action was a rerun of the standard COVID trade.
Those rattles you hear on the COVID, Fed and political fronts are reasons to tread carefully in the markets.
Here's how the U.S. can play a critical part in defending the island from COVID -- and mainland China.
Moderna has been a winner, but here's why traders should raise stops.
These companies were counted out way too early in the post-pandemic environment and the sellers are experiencing some real regret.
The greenback has maintained a higher level of relative strength versus its peer reserve currencies than I would have thought.
There's a split growing at the FOMC as to just how transitory the current burst of consumer level inflation actually is.
These names are displaying both quantitative and technical deterioration.
CVAC is now working on a 'next generation' COVID-19 vaccine candidate with GlaxoSmithKline.
And I was right, and the cynics were wrong. Here's why that matters more than ever now.
I prefer the bear put spread over the covered equity play due to the decreased risk to principal, despite the capped potential for profit.
Plus, it appears there may be headway on an infrastructure bill that could work for both sides of the aisle.
We've been caught with our pants down, largely because we had no faith in the smartest people in the country.
Debt-free and poised to gain from its COVID-19 vaccine demand, MRNA could inject some life into your investment plan.
The market seems to rejoice from the latest mask utterance out of the CDC, but the action at the Nasdaq should give traders pause.
ARCT's IP is incredibly valuable, and may in fact be invaluable.
The fund is at a key spot technically, and there is real fear that if this spot cracks, what looks like a stretch of rough rapids could become a waterfall.
UPS and FDX are both in serious rally mode, yet in very different places in terms of technical development.
Perhaps the most interesting result of an inflationary but not frightening CPI was visible in U.S. Treasury security markets.
You never want to be caught in a counter trend rally.
Don't forget, this is a very large company with a lot more than the vaccine going on.
I would argue that the pandemic has lasted just long enough to wipe out the little guy and let the bigger guys have the run of the joint.
My COVID vaccine eligibility actually began about a week before my symptoms began.
A buy-write makes sense here, but the premiums are tight, so I'd rather do a buy-ratio spread.
Outside of the pro sports world, it seems like amateur hour with regard to protocols.
Here's my view on this space and where the money is to be made.